PRNewsWire
20 Nov 2025, 15:00 UTC · 48w ago
Verdict
Headline takes no side. We score PRLD −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Prelude Therapeutics has paused the clinical development of its SMARCA2 degrader program.
More negative than 99% of claims this week
Pomerantz LLP is investigating Prelude Therapeutics for potential securities fraud or unlawful business practices.
So whatLegal investigations into corporate misconduct increase regulatory risk and can lead to costly settlements or further stock devaluation.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 91% of claims this week
Prelude Therapeutics' stock price dropped 55.78% following the announcement to pause the SMARCA2 program.
So whatWhile this is a historical price move, it confirms the market's high valuation of the paused program.
More negative than 69% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a securities fraud investigation following a 55.78% stock price drop and the pausing of a clinical program.
More negative than 87% of ticker scores this week
The company is being investigated by Pomerantz LLP for potential claims on behalf of investors.
More negative than 87% of ticker scores this week
The company is being investigated by Pomerantz LLP for potential claims on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
3h ago
+117.4%
Price is moving against the score
$3.63 vs $1.67 close before publication (Nov 19) · not market-adjusted
PRLD chart →
